ZAAPS program results for 2010: An activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries

Journal of Chemotherapy

Volumn 24, Issue 6, 2012, Pages 328-337

  Flamm, Robert K ^a   Farrell, David J ^a   Mendes, Rodrigo E ^a   Ross, James E ^a   Sader, Helio S ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Linezolid; Oxazolidinones; Surveillance; ZAAPS

Indexed keywords

AMPICILLIN; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ASIA; BACTERIAL STRAIN; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; BRAZIL; BROTH DILUTION; CANADA; CHINA; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DISK DIFFUSION; DRUG DETERMINATION; DRUG POTENCY; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; EPIDEMIC; EUROPE; GERMANY; GRAM POSITIVE ASPOROGENOUS ROD-SHAPED BACTERIA; HEALTH PROGRAM; HUMAN; IN VITRO STUDY; ITALY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MEXICO; MINIMUM INHIBITORY CONCENTRATION; SOUTH AND CENTRAL AMERICA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HOMINIS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; THAILAND; ZAAPS PROGRAM;

ACETAMIDES; ANTI-BACTERIAL AGENTS; ASIA; AUSTRALIA; CANADA; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS; EUROPE; HUMANS; LATIN AMERICA; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; PUBLIC HEALTH SURVEILLANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS;

EID: 84870790006     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947812Y.0000000039     Document Type: Article

References (48)

1. Beibei L, Yun C, Mengli C, Nan B, Xuhong Y, Rui W. Linezolid versus vancomycin for the treatment of grampositive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2010;35:3-12.
2. Bounthavong M, Hsu DI. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): A meta-analysis. Curr Med Res Opin. 2010;26:407-21.
3. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet. 2001;358:1975-82.
4. Eliopoulos GM. Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria. J Infect. 2009;59(Suppl 1):S17-24.
5. Ford CW, Zurenko GE, Barbachyn MR. The discovery of linezolid, the first oxazolidinone antibacterial agent. Curr Drug Targets Infect Disord. 2001;1:181-99.
6. Zyvox (2010). Package Insert. [accessed 2012 February]. Available from http://www.pfizer.com/products/rx/rx_product_ zyvox.jsp
7. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: A randomized, controlled study. Clin Infect Dis. 2012;54:621-9.
8. Gomez-Gil R, Romero-Gomez MP, Garcia-Arias A, Ubeda MG, Busselo MS, Cisterna R, et al. Nosocomial outbreak of linezolid-resistant Enterococcus faecalis infection in a tertiary care hospital. Diagn Microbiol Infect Dis. 2009;65:175-9.
9. Schulte B, Heininger A, Autenrieth IB, Wolz C. Emergence of increasing linezolid-resistance in enterococci in a post-outbreak situation with vancomycin-resistant Enterococcus faecium. Epidem Infect. 2008;136:1131-3.
10. Gales AC, Sader HS, Andrade SS, Lutz L, Machado A, Barth AL. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int J Antimicrob Agents. 2006;27:300-2.
11. Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis. 2004;39:1010-5.
12. Mutnick AH, Enne V, Jones RN. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann Pharmacother. 2003;37:769-74.
13. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001;358:207-8.
14. Jones RN, Della-Latta P, Lee LV, Biedenbach DJ. Linezolidresistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: Report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis. 2002;42:137-9.
15. Liakopoulos A, Spiliopoulou I, Damani A, Kanellopoulou M, Schoina S, Papafragas E, et al. Dissemination of two international linezolid-resistant Staphylococcus epidermidis clones in Greek hospitals. J Antimicrob Chemother. 2010;65:1070-1.
16. Liakopoulos A, Neocleous C, Klapsa D, Kanellopoulou M, Spiliopoulou I, Mathiopoulos KD, et al. A T2504A mutation in the 23S rRNA gene responsible for high-level resistance to linezolid of Staphylococcus epidermidis. J Antimicrob Chemother. 2009;64:206-7.
17. Wong A, Reddy SP, Smyth DS, Aguero-Rosenfeld ME, Sakoulas G, Robinson DA. Polyphyletic emergence of linezolid-resistant staphylococci in the United States. Antimicrob Agents Chemother. 2010;54:742-8.
18. Mendes RE, Deshpande LM, Castanheira M, DiPersio J, Saubolle MA, Jones RN. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother. 2008;52:2244-6.
19. Mendes RE, Deshpande L, Rodriguez-Noriega E, Ross JE, Jones RN, Morfin-Otero R. First report of staphylococcal clinical isolates in Mexico with linezolid resistance caused by cfr: evidence of in vivo cfr mobilization. J Clin Microbiol. 2010;48:3041-3.
20. Morales G, Picazo JJ, Baos E, Candel FJ, Arribi A, Pelaez B, et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis. 2010;50:821-5.
21. Ballow CH, Biedenbach DJ, Rossi F, Jones RN. Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: Report of the Zyvox(R) Antimicrobial Potency Study in Latin America (LA-ZAPS). Braz J Infect Dis. 2002;6:100-9.
22. Ballow CH, Jones RN, Biedenbach DJ. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn Microbiol Infect Dis. 2002;43:75-83.
23. Bell JM, Turnidge JD, Ballow CH, Jones RN. Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific. J Antimicrob Chemother. 2003;51:339-45.
24. Bolmstrom A, Ballow CH, Qwarnstrom A, Biedenbach DJ, Jones RN. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: Report from the Zyvox antimicrobial potency study (ZAPS-Europe). Clin Microbiol Infect. 2002;8:791-800.
25. Jones RN, Ballow CH, Biedenbach DJ. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States. Diagn Microbiol Infect Dis. 2001;40:59-66.
26. Anderegg TR, Sader HS, Fritsche TR, Ross JE, Jones RN. Trends in linezolid susceptibility patterns: Report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. Int J Antimicrob Agents. 2005;26:13-21.
27. Ross JE, Fritsche TR, Sader HS, Jones RN. Oxazolidinone susceptibility patterns for 2005: International report from the ZyvoxH Annual Appraisal of Potency and Spectrum Study. Int J Antimicrob Agents. 2007;29:295-301.
28. Draghi DC, Sheehan DJ, Hogan P, Sahm DF. In vitro activity of linezolid against key gram-positive organisms isolated in the United States: Results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother. 2005;49:5024-32.
29. Draghi DC, Sheehan DF, Hogan P, Sahm DF. Current antimicrobial resistance profiles among methicillin-resistant Staphylococcus aureus encountered in the outpatient setting. Diagn Microbiol Infect Dis. 2006;55:129-33.
30. Jones RN, Fritsche TR, Sader HS, Ross JE. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn Microbiol Infect Dis. 2007;59:309-17.
31. Jones RN, Ross JE, Castanheira M, Mendes RE. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn Microbiol Infect Dis. 2008;62:416-26.
32. Farrell DJ, Mendes RE, Ross JE, Jones RN. Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagn Microbiol Infect Dis. 2009;65:392-403.
33. Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. LEADER Program results for 2009: An activity and spectrum analysis of linezolid using 6,414 clinical isolates from the United States (56 Medical Centers). Antimicrob Agents Chemother. 2011;55:3684-90.
34. Pillar CM, Draghi DC, Sheehan DJ, Sahm DF. Prevalence of multidrug-resistant, methicillin-resistant Staphylococcus aureus in the United States: Findings of the stratified analysis of the 2004 to 2005 LEADER Surveillance Programs. Diagn Microbiol Infect Dis. 2008;60:221-4.
35. Biedenbach DJ, Farrell DJ, Mendes RE, Ross JE, Jones RN. Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: Results from the 2009 Zyvox(R) Annual Appraisal of Potency and Spectrum program. Diagn Microbiol Infect Dis. 2010;68:459-67.
36. Jones RN, Fritsche TR, Sader HS, Ross JE. ZyvoxH Annual Appraisal of Potency and Spectrum Program results for 2006: An activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagn Microbiol Infect Dis. 2007;59:199-209.
37. Jones RN, Kohno S, Ono Y, Ross JE, Yanagihara K. ZAAPS International Surveillance Program (2007) for linezolid resistance: Results from 5591 Gram-positive clinical isolates in 23 countries. Diagn Microbiol Infect Dis. 2009;64:191-201.
38. Ross JE, Anderegg TR, Sader HS, Fritsche TR, Jones RN. Trends in linezolid susceptibility patterns in 2002: Report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagn Microbiol Infect Dis. 2005;52:53-8.
39. CLSI. M07-A8. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: eighth edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
40. CLSI. M100-S21. Performance standards for antimicrobial susceptibility testing: 21st informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.
41. CLSI. M02-A10. Performance standards for antimicrobial disk susceptibility tests; approved standard: tenth edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
42. Locke JB, Hilgers M, Shaw KJ. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Chemother. 2009;53:5265-74.
43. Locke JB, Hilgers M, Shaw KJ. Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin. Antimicrob Agents Chemother. 2009;53:5275-8.
44. Mendes RE, Deshpande LM, Farrell DJ, Spanu T, Fadda G, Jones RN. Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy. J Antimicrob Chemother. 2010;65:2329-35.
45. Jones RN, Ross JE, Bell JM, Utsuki U, Fumiaki I, Kobayashi I, et al. Zyvox Annual Appraisal of Potency and Spectrum program: Linezolid surveillance program results for 2008. Diagn Microbiol Infect Dis. 2009;65:404-13.
46. Diaz L, Kiratisin P, Mendes R, Panesso D, Singh KV, Arias CA. Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis. Antimicrob Agents Chemother. 2012;56:3917-22.
47. Liu Y, Wang Y, Wu C, Shen Z, Schwarz S, Du XD, et al. First report of the multidrug resistance gene cfr in Enterococcus faecalis of animal origin. Antimicrob Agents Chemother. 2012;56:1650-4.
48. Cercenado E, Marin M, Insa R, Bouza E. Emerging linezolid resistance: dissemination of the cfr gene among Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecium and Enterococcus faecalis and inability of the Etest method for detection. 50th ICAAC, 2010 September 12-15, Boston, MA, USA. Abstr. C2-1490.